【Anti-Virus 抗病毒】Absoluteantibody重組抗體系列商品
Anti-Virus 抗病毒重組抗體系列商品
Absoluteantibody提供一系列針對病毒抗原的重組抗體。抗體最初通過Hybridoma技術，phage-display噬菌體展示技術或來自感染的人類患者的（永生化）B細胞的sequencing產生。使用Cellclone技術從真實的人類患者中提供了一系列由Humabs BioMed SA產生的抗體。抗體適用於pre-clinical research臨床前研究，並對下列用途進行驗證。
牛痘病毒A14磷蛋白/ 病毒體膜蛋白A14 | 貨號: Ab00733-1.1
產品介紹: A14的重組單株抗體Mouse IgG1, kappa (Clone Number: BB5.2)。使用來自雜交瘤BB5.2的可變區（即特異性）。免疫原：該抗體通過用WR.K1L-C7L-（一種高度注意的痘苗病毒）鼻內感染BALB / c小鼠而產生之抗體。隨後用鼻內接種野生型VACV攻擊小鼠，然後用UV滅活的VACV靜脈內注射。特異性：該抗體特異於痘苗病毒A14磷蛋白，其在細胞內成熟病毒粒子的膜上表達。A14是一組引起強多克隆抗體反應的VAVC蛋白質之一，導致針對相同蛋白質產生多個Clone之Hybridoma，可應用於IF，IP和WB實驗。
E2糖蛋白的B結構域 / CHIKV E2 B結構域 | 貨號Ab00687-1.1
產品介紹: E2蛋白重組單株抗體Mouse IgG1, lambda (Chk265)。使用來自雜交瘤Chk265的可變區（即特異性）。免疫原：La Reunion 2006將OPO-1株CHIKV注射入具有後續增強劑的干擾素調節因子7缺失的成年C57BL / 6小鼠中。特異性：該抗體結合甲病毒的E2糖蛋白的B結構域，如基孔肯雅病毒，O’nyong’nyong病毒，Ross River病毒，Semliki Forest病毒，Mayaro病毒，Una病毒，Getah病毒，Bebaru病毒，Middelburg病毒 巴馬森林病毒。該抗體結合甲病毒的E2糖蛋白的B結構域，並在體內防止疾病和病毒傳播。
E蛋白三聚體（DENV3）/ 包膜蛋白三聚體 | 貨號Ab00834-10.3
產品介紹: E蛋白三聚體（DENV3）重組單株抗體Human IgG1, Fc Silent™, kappa (Clone Number: 5J7)。使用來自B細胞克隆5J7可變區（即特異性）。免疫原： Envelope protein trimer Immunogen: The original hybridoma was generated by fusing anti-Dengue antibody producing, EBV immortalised B-cells from a DENV-immune patient, with HMMA2.5 myeloma cells.特異性：該抗體結合登革熱病毒3包膜蛋白。 DI-DII鉸鏈中的單一突變（Q269和N270之間的賴氨酸插入）消除結合。 Fibriansah等人（2015，PMID：25698059）報導5J7 Fab結合三個包膜蛋白，並且與三個功能重要的結構域結合，各自在不同的蛋白質上。該抗體通過ELISA和流式細胞術結合DENV3E蛋白。 也已顯示中和DENV3病毒，而不是DENV1，DENV2或DENV4。
Anti-dsRNA 雙股RNA / 雙鏈核糖核酸單株抗體 [1D3] | 貨號Ab00460-1.1
產品介紹: Anti-dsRNA 雙股RNA重組單株抗體Mouse IgG1, kappa (Clone Number: 1D3)。使用來自雜交瘤1D3可變區（即特異性）。免疫原：RDV-RNA甲基化牛血清白蛋白複合物。特異性：抗體特異性結合ds-RNA，這是一些病毒的遺傳物質的一部分，如輪狀病毒和藍舌病毒。 該抗體可用作診斷工具，以確定未知病原體的性質，並可能用於基因治療。
HA Influenza A Virus 單株抗體 [FB75] | 貨號Ab00148-1.1
產品介紹: HA重組單株抗體Mouse IgG1, lambda (Clone Number: FB75)。使用來自EBV轉化的人B細胞克隆FB75可變區（即特異性）。免疫原通過Influenza A Virus (several subtypes)季節性流感疫苗接種個體後，將IgG表達的B細胞永生化，含有H1和H3流感病毒亞型。特異性：該抗體特異性識別HA的莖區中的構象表位，其中氨基酸序列在甲型流感病毒的H1N1，H5N1，H6N1和H9N2亞型中高度保守。 該抗體使用VH3-23 * 01，D3-3 * 01，JH4 * 02，VL2-23 * 02和JL1 * 01。 該抗體不與甲型流感病毒的H2N2，H3N2和H7N7亞型中的HA交叉反應。 該抗體對血細胞凝集抑制活性無影響。
Published Application(s): NTRL; ELISA Published Species Reactivity: Influenza A Virus (several subtypes)
Anti-VP1 [4C4] 口蹄疫病毒重組單株抗體 | 貨號Ab00939-2.0
產品介紹: VP1口蹄疫病毒重組單株抗體 / 小鼠IgG2a，kappa (Clone Number: 4C4)。使用來自雜交瘤4C4的可變區可變區（即特異性）。免疫原針對FMDV的C1型Brescia It / 64菌株產生鼠抗體。特異性：4C4特異性結合C型FMDV衣殼蛋白VP1的G-H環，也稱抗原位點A.這種特異性由斑塊減少中和測定（Verdaguer等人，1999）以及更近期的晶體學數據（Verdaguer等人，1998; Ochoa等人，2000）支持。 VP1是宿主細胞識別所需的外殼蛋白，並且可以促進感染期間的FMDV進入。口蹄疫會影響牛種，在某些情況下可能是致命的。4C4對血清型C FMDV的VP1 G-H環或抗原性位點A具有強烈的中和活性。已經使用噬菌斑減少（中和）測定以及ELISA和免疫印跡（Mateu等人，1992,1989,1990）。
Published Application(s): NTRL; crystallisation; ELISA; WB Published Species Reactivity: Foot-and-mouth disease virus
病毒抗體 Anti-VP1 | HA Influenza A Virus 單株抗體 | 牛痘病毒A14磷蛋白 | CHIKV E2 B結構域 | CHIKV E2 B結構域 | E蛋白三聚體（DENV3）
| Product Name | Expected Species Reactivity | Applications |
|---|---|---|
| Anti-A14 [BB5.2] | Vaccinia virus | WB; IP; IF |
| Anti-avian infectious bronchitis virus nucleoprotein [C5P1] | avian infectious bronchitis virus | ELISA; WB |
| Anti-CD205 [scFv DEC-205] | Mouse | vaccination |
| Anti-CD5 [OX-19] | Rat | WB; IHC; inhibit; FC |
| Anti-CMV glycoprotein gB [HCMV37] | CMV | NTRL; ELISA; IHC-Fr; IF; ICC |
| Anti-CPV capsid [14] | canine parovirus (CPV) | neutralize; crystallize; cryoEM |
| Anti-Cytomegalovirus (CMV) gH glycoprotein [MSL-109] | CMV | NTRL |
| Anti-DI/DII domain of Dengue E protein [DV18] | Dengue Virus | ELISA; NTRL |
| Anti-DI/DII domain of Dengue E protein [DV78] | Dengue Virus | ELISA; NTRL |
| Anti-DIII domain of Dengue E protein (DENV-1 and DENV-3) [DV63] | Dengue Virus | ELISA; NTRL |
| Anti-DIII domain of Dengue E protein [DV10] | Dengue Virus | ELISA; NTRL |
| Anti-dsRNA [1D3] | Virus | ELISA; IHC; WB |
| Anti-dsRNA [9D5] | Virus | ELISA; IHC; WB |
| Anti-E-protein DIII (ABDE) [ZV-2] | Zika Virus | crystallization; SPR; FC |
| Anti-E-protein DIII (C-C’) [ZV-48] | Zika Virus | NTRL; crystallization; SPR; FC |
| Anti-E-protein DIII (C-C’) [ZV-64] | Zika Virus | NTRL; crystallization; SPR; FC |
| Anti-E-protein DIII (LR) [ZV-67] | Zika Virus | NTRL; crystallization; SPR; FC |
| Anti-E-protein trimer (DENV3) [5J7] | Dengue Virus (all subtypes) | ELISA; FC; NTRL; cryo-EM |
| Anti-E2 A domain [F5] | Human Venezuelan Equine Encephalitis Virus | NTRL; crystallization |
| Anti-E2 B domain [3b4c-4] | Human Venezuelan Equine Encephalitis Virus | ELISA; NTRL; crystallization |
| Anti-E2 protein [4J21] | Chikungunya | NTRL; crystallization; ELISA |
| Anti-E2 protein [Chk265] | Chikungunya; Alphaviruses | NTRL; ELISA; crystallization; IF; FC |
| Anti-Ebola GP [h-13F6] | EBOV (Zaire) | IP; SPR; ELISA |
| Anti-Ebola Nucleoprotein [KZ51] | Ebola Virus (Zaire, Ivory Coast, Reston, Sudan) | ELISA; WB; IP; IF |
| Anti-Ebola surface glycoprotein [KZ52] | Ebola (Zaire) | NTRL; IF; IP; crystallization |
| Anti-EDIII [2D73] | DENV | ELISA; crystallisation |
| Anti-Envelope dimer Epitope 1 [752-2C8] | Dengue Virus; Zika Virus | NTRL; ELISA; crystallization |
| Anti-Envelope dimer Epitope 1 [753(3) C10] | Dengue Virus; Zika Virus | NTRL; ELISA; crystallization |
| Anti-Envelope dimer Epitope 2 [747(4) A11] | Dengue Virus; Zika Virus | NTRL; ELISA; crystallization |
| Anti-Envelope dimer Epitope 2 [747(4) B7] | Dengue Virus; Zika Virus | NTRL; ELISA; crystallization |
| Anti-Envelope glycoprotein Gc [A5] | Hantavirus | crystallization; SPR |
| Anti-Envelope protein [ZKA64] | Zika Virus | NTRL; enhance; FC; ELISA |
| Anti-Envelope protein [ZKA78] | Zika Virus; Dengue Virus | NTRL; enhance; FC; ELISA |
| Anti-Envelope protein DIII [E111] | DENV-1 | NTRL; FC; WB; IP; IHC; IF |
| Anti-Filovirus GP [Mr78] | Marburg Virus; Ebola Virus | NTRL; ELISA |
| Anti-Flavivirus group antigen [D1-4G2-4-15 (4G2)] | Dengue Virus; Zika Virus; West Nile Virus; Yellow Fever Virus; Flaviviridae | IF; WB; NTRL; ELISA; FC; IHC-P |
| Anti-gH [YC15] | KSHV | WB; NTRL; IHC; FC |
| Anti-gH [YC15] | KSHV | FC; NTRL |
| Anti-Glycoprotein D of HSV [E317] | Herpes Simplex Virus | ELISA; IP; Blocking |
| Anti-Glycoprotein H [A13-d6.3] | pseudorabies virus (PrV) | neutralize; crystalize; immunostaining |
| Anti-GP1 [GD01] | Junin virus (JUNV) | neutralize; crystallize; ELISA |
| Anti-H3N2 antigen from influenza A virus [IF1A11] | Influenza A | ELISA; WB; Blocking |
| Anti-HA [FB75] | Influenza A Virus (several subtypes) | NTRL; ELISA |
| Anti-HA [FC41] | Influenza A Virus (several subtypes) | ELISA |
| Anti-HA [FE17] | Influenza A Virus (several subtypes) | ELISA |
| Anti-HBeAg [E6] | Hep B | Mab: RIA; cross-competition assay; serum protein electrophoresis. Fab; crystallization |
| Anti-HBsAg [5C3] | Hepatitis B Virus | RIA |
| Anti-HBsAg [F124 scFv] | Hepatitis B Virus | ELISA |
| Anti-HBsAg [F124] | Hepatitis B virus | WB; NTRL; RIA |
| Anti-Hemagglutinin 5 [H5.3] | Influenza virus H5N1 (VN/1203; HK/156; Anhui; Indo) | Neutralize |
| Anti-HepA [HA1] | Virus (HepA) | Radioimmunofocus inhibition assays; ELISA; |
| Anti-HepA [HA12] | Virus (HepA) | Radioimmunofocus inhibition assays; ELISA; |
| Anti-HepA [HA6] | Virus (HepA) | Radioimmunofocus inhibition assays; ELISA; |
| Anti-Hepatitis A virus capsid [R10] | Hepatitis A Virus | Neutralisation; ELISA; crystallisation |
| Anti-HIV-1 GP120 [HGD65] | HIV-1 | NTRL |
| Anti-HIV-1 GP120 [HGN194] | HIV-1 | NTRL |
| Anti-HIV-1 GP120 [HGZ1] | HIV-1 | NTRL |
| Anti-HIV-1 GP120 [HJ16] | HIV-1 | NTRL |
| Anti-HIV-1 GP120 [HR10] | HIV-1 | NTRL |
| Anti-HIV-1 GP120 [HR12] | HIV-1 | NTRL |
| Anti-HIV-1 GP41 [HGF24] | HIV-1 | NTRL |
| Anti-HIV-1 GP41 [HK20] | HIV-1 | NTRL |
| Anti-HIV-1 protease [F11.2.32] | HIV-1 | neutralize; ELISA |
| Anti-HIV-1/HIV-2 protease [1696] | HIV-1; HIV-2 | Neutralize; ELISA; WB |
| Anti-infectious bursal disease virus [CRAb154] | infectious bursal disease virus | ELISA; IP |
| Anti-infectious bursal disease virus VP2 [CRAb 88] | very virulent infectious bursal disease virus (CS89) | ELISA; IP |
| Anti-Influenza A HA [FLD127] | H5N1 Influenza A Virus | NTRL; ELISA; RIA |
| Anti-Influenza A HA [FLD20] | H5N1 Influenza A Virus | NTRL |
| Anti-Influenza A HA [FLD21] | H5N1 Influenza A Virus | NTRL |
| Anti-Influenza A HA [FLD84] | H5N1 Influenza A Virus | NTRL; ELISA; RIA |
| Anti-Influenza A HA [FLD93] | H5N1 Influenza A Virus | NTRL |
| Anti-Influenza A HA [HA] | Influenza A Virus (several subtypes) | ELISA |
| Anti-JEV virions (E/PrM) [TJE12B02] | Japanese Encephalitis Virus | NTRL; ELISA; IP |
| Anti-MERS-CoV Spike Protein [4c2] | MERS-CoV | NTRL; ELISA; Crystallization |
| Anti-MERS-CoV Spike Protein [D12] | MERS-CoV | NTRL; ELISA; Crystallization; IF |
| Anti-Neutralizing Epitope [ZKA185] | Zika Virus | NTRL |
| Anti-Norovirus GII.4 [NVB43.9] | Norovirus | NTRL; Block |
| Anti-NS1 [22NS1] | West Nile virus | NTRL; FC; crystallography |
| Anti-Parvovirus [MAbE] | canine parvovirus; feline panleukopenia virus | IP; RIA; ELISA; neutralisation; EM |
| Anti-Poxvirus L1 Protein [Fab 7d11] | Poxviruses | ELISA; PRNT; crystallization |
| Anti-pre- and post-fusion confirmation of HRSV F protein [RSB15] | Respiratory Syncytial Virus (RSV) | IF; NTRL |
| Anti-pre- and post-fusion confirmation of HRSV F protein [RSB16] | Respiratory Syncytial Virus (RSV) | IF; NTRL |
| Anti-pre-fusion confirmation of HRSV F protein [RSB20] | Respiratory Syncytial Virus (RSV) | IF; NTRL |
| Anti-pre-fusion confirmation of HRSV F protein [RSB43] | Respiratory Syncytial Virus (RSV) | IF; NTRL |
| Anti-Rabies Virus 67kDa protein [EP5G3] | Rabies Virus | WB; NTRL; IP; ELISA |
| Anti-Rabies Virus 67kDa protein [Fab094] | Rabies Virus | WB; NTRL; ELISA; IP |
| Anti-Rabies Virus 67kDa protein [GD2D12] | Rabies Virus | WB; NTRL; IP; ELISA |
| Anti-RRV E2 [D7] | Ross River Virus | FC; labelling |
| Anti-RSV [RSHZ19 (Felvizumab)] | RSV | functional; ELISA |
| Anti-SARS-CoV S glycoprotein [S109] | SARS Virus | ELISA; NTRL |
| Anti-SARS-CoV S glycoprotein [S110] | SARS Virus | ELISA; NTRL |
| Anti-SARS-CoV S glycoprotein [S124] | SARS Virus | ELISA; NTRL |
| Anti-SARS-CoV S glycoprotein [S215] | SARS Virus | ELISA; NTRL |
| Anti-SARS-CoV S glycoprotein [S217] | SARS Virus | ELISA; NTRL |
| Anti-SARS-CoV S glycoprotein [S222] | SARS Virus | ELISA; NTRL |
| Anti-SARS-CoV S glycoprotein [S223] | SARS Virus | ELISA; NTRL |
| Anti-SARS-CoV S glycoprotein [S225] | SARS Virus | ELISA; NTRL |
| Anti-SARS-CoV S glycoprotein [S226] | SARS Virus | ELISA; NTRL |
| Anti-SARS-CoV S glycoprotein [S227] | SARS Virus | ELISA; NTRL |
| Anti-SARS-CoV S glycoprotein [S228] | SARS Virus | ELISA; NTRL |
| Anti-SARS-CoV S glycoprotein [S230] | SARS Virus | ELISA; NTRL |
| Anti-SARS-CoV S glycoprotein [S231] | SARS Virus | ELISA; NTRL |
| Anti-sE [Z20] | Zika virus | NTRL; crystallisation; ELISA; FC; SPR |
| Anti-sE [Z23] | Zika virus | NTRL; ELISA; FC; SPR |
| Anti-sE [Z3L1] | Zika virus | NTRL; crystallisation; ELISA; FC; SPR |
| Anti-Sigma1 [5C6] | Reovirus strain T1L | IF; NTRL; IP; FC; crystallisation |
| Anti-Sigma1 [9BG5] | Reovirus strain T3D | RIA; IP; FC; crystallisation |
| Anti-SV40 large Tumor Antigen [405] | SV40 | WB; ELISA |
| Anti-V5 epitope tag [SV5-P-K] | Paramyxovirus Simian Virus 5 | ELISA; IF; IHC-Fr; IP; RIA; WB |
| Anti-Vaccinia A33 glycoprotein [A2C7] | Vaccinia virus | IF; neutralization |
| Anti-Vaccinia L1 protein [M12b9 Fab] | Vaccinia virus | crystallization; BLI binding assay |
| Anti-VP1 [4C4] | Foot-and-mouth disease virus | NTRL; crystallisation; ELISA; WB |
| Anti-WNV Envelope protein [9E2] | West Nile virus | NTRL; WB |
| Anti-WNV Envelope protein DI-DII [E53] | West Nile virus | NTRL; crystallography |
| Anti-WNV Envelope protein DIII [E16] | West Nile virus | NTRL; crystallography |
| Anti-ZIKV soluble envelope protein [z23] | Zika virus | Block |